APOH and autoimmune polyendocrinopathy: Previous studies have reported a positivity rate for anti-β2GPI-D1 in seronegative APS patients ranging from absent or low (<5%) to as high as 16% (35, 38, 40, 56, 57), supporting its potential utility in this subset of patients.